免疫反应阻碍了溶酶体贮积症的治疗。
Immune response hinders therapy for lysosomal storage diseases.
作者信息
Ponder Katherine P
机构信息
Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
出版信息
J Clin Invest. 2008 Aug;118(8):2686-9. doi: 10.1172/JCI36521.
Abstract
Enzyme replacement therapy (ERT) for the lysosomal storage disease mucopolysaccharidosis I (MPS I) involves i.v. injection of alpha-l-iduronidase, which can be taken up by cells throughout the body. While a significant immune response to ERT has been shown in patients with MPS I, little is known about what effect anti-enzyme antibodies have on treatment efficacy. In this issue of the JCI, Dickson et al. demonstrate that anti-enzyme antibodies inhibit enzyme uptake and substantially limit the therapeutic efficacy of ERT in canines with MPS I (see the related article beginning on page 2868). Furthermore, the induction of immune tolerance--via oral delivery of cyclosporine A and azathioprine for two months at the time of initiation of ERT with recombinant human alpha-L-iduronidase--improved enzyme uptake in organs. Therefore, transient immunosuppression may enhance ERT for lysosomal storage diseases.
摘要
用于溶酶体贮积病黏多糖贮积症I型（MPS I）的酶替代疗法（ERT）涉及静脉注射α-L-艾杜糖醛酸酶，该酶可被全身细胞摄取。虽然已在MPS I患者中显示出对ERT的显著免疫反应，但对于抗酶抗体对治疗效果有何影响却知之甚少。在本期《临床研究杂志》中，迪克森等人证明抗酶抗体抑制酶摄取，并在很大程度上限制了ERT对患有MPS I的犬类的治疗效果（见第2868页开始的相关文章）。此外，在开始使用重组人α-L-艾杜糖醛酸酶进行ERT时，通过口服环孢素A和硫唑嘌呤两个月来诱导免疫耐受，可改善器官中的酶摄取。因此，短暂的免疫抑制可能会增强针对溶酶体贮积病的ERT效果。
相似文献
1
Immune response hinders therapy for lysosomal storage diseases.
J Clin Invest. 2008 Aug;118(8):2686-9. doi: 10.1172/JCI36521.
2
Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
J Clin Invest. 2008 Aug;118(8):2868-76. doi: 10.1172/JCI34676.
3
Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I.
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):829-34. doi: 10.1073/pnas.0305480101. Epub 2004 Jan 8.
4
Effects of neonatal enzyme replacement therapy and simvastatin treatment on cervical spine disease in mucopolysaccharidosis I dogs.
J Bone Miner Res. 2014 Dec;29(12):2610-7. doi: 10.1002/jbmr.2290.
5
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
Mol Genet Metab. 2004 Sep-Oct;83(1-2):163-74. doi: 10.1016/j.ymgme.2004.07.003.
6
Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.
Biochem Mol Med. 1996 Aug;58(2):156-67. doi: 10.1006/bmme.1996.0044.
7
Enzyme replacement therapy in feline mucopolysaccharidosis I.
Mol Genet Metab. 2001 Mar;72(3):199-208. doi: 10.1006/mgme.2000.3140.
8
Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats.
Mol Genet Metab. 2000 Apr;69(4):277-85. doi: 10.1006/mgme.2000.2979.
9
Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
Mol Genet Metab. 2016 Sep;119(1-2):124-30. doi: 10.1016/j.ymgme.2016.06.006. Epub 2016 Jun 8.
10
Changes in hair morphology of mucopolysaccharidosis I patients treated with recombinant human alpha-L-iduronidase (laronidase, Aldurazyme).
Am J Med Genet A. 2005 Dec 15;139(3):199-203. doi: 10.1002/ajmg.a.31021.
引用本文的文献
1
Assessment of different promoters in lentiviral vectors for expression of the N-acetyl-galactosamine-6-sulfate sulfatase gene.
J Hum Genet. 2025 Jun 10. doi: 10.1038/s10038-025-01353-x.
2
CRISPR/nCas9-Edited CD34+ Cells Rescue Mucopolysaccharidosis IVA Fibroblasts Phenotype.
Int J Mol Sci. 2025 May 2;26(9):4334. doi: 10.3390/ijms26094334.
3
Antibodies to recombinant human alpha-L-iduronidase prevent disease correction in cortical bone in MPS I mice.
Mol Ther Methods Clin Dev. 2025 Jan 2;33(1):101405. doi: 10.1016/j.omtm.2024.101405. eCollection 2025 Mar 13.
4
Lentiviral gene therapy prevents anti-human acid α-glucosidase antibody formation in murine Pompe disease.
Mol Ther Methods Clin Dev. 2022 May 4;25:520-532. doi: 10.1016/j.omtm.2022.04.016. eCollection 2022 Jun 9.
5
Immunological barriers to haematopoietic stem cell gene therapy.
Nat Rev Immunol. 2022 Dec;22(12):719-733. doi: 10.1038/s41577-022-00698-0. Epub 2022 Mar 17.
6
Systemic diseases and the cornea.
Exp Eye Res. 2021 Mar;204:108455. doi: 10.1016/j.exer.2021.108455. Epub 2021 Jan 21.
7
Cyclosporin A but not FK506 activates the integrated stress response in human cells.
J Biol Chem. 2020 Oct 30;295(44):15134-15143. doi: 10.1074/jbc.RA120.014531. Epub 2020 Aug 24.
8
Targeting Macromolecules to CNS and Other Hard-to-Treat Organs Using Lectin-Mediated Delivery.
Int J Mol Sci. 2020 Feb 1;21(3):971. doi: 10.3390/ijms21030971.
9
Biodegradable polyethylene glycol hydrogels for sustained release and enhanced stability of rhGALNS enzyme.
Drug Deliv Transl Res. 2020 Oct;10(5):1341-1352. doi: 10.1007/s13346-020-00714-7.
10
Oral immunotherapy tolerizes mice to enzyme replacement therapy for Morquio A syndrome.
J Clin Invest. 2020 Mar 2;130(3):1288-1300. doi: 10.1172/JCI125607.
本文引用的文献
1
Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
J Clin Invest. 2008 Aug;118(8):2868-76. doi: 10.1172/JCI34676.
2
Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
Mol Genet Metab. 2008 Jul;94(3):313-8. doi: 10.1016/j.ymgme.2008.03.008. Epub 2008 May 5.
3
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model.
Clin Exp Immunol. 2008 Apr;152(1):138-46. doi: 10.1111/j.1365-2249.2008.03602.x. Epub 2008 Feb 25.
4
Treatment of lysosomal storage disorders : progress with enzyme replacement therapy.
Drugs. 2007;67(18):2697-716. doi: 10.2165/00003495-200767180-00005.
5
Effect of immunosuppressants on the expansion and function of naturally occurring regulatory T cells.
Transpl Immunol. 2007 Nov;18(2):94-100. doi: 10.1016/j.trim.2007.05.005. Epub 2007 Jun 14.
6
Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.
Am J Hum Genet. 2007 Nov;81(5):1042-9. doi: 10.1086/522236. Epub 2007 Sep 21.
7
Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors.
Transplant Proc. 2007 Sep;39(7):2290-2. doi: 10.1016/j.transproceed.2007.07.076.
8
Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
Pediatrics. 2007 Jul;120(1):e37-46. doi: 10.1542/peds.2006-2156. Epub 2007 Jun 4.
9
Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells.
Am J Transplant. 2007 Jul;7(7):1722-32. doi: 10.1111/j.1600-6143.2007.01842.x. Epub 2007 May 19.
10
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease.
Neurology. 2007 Jan 9;68(2):99-109. doi: 10.1212/01.wnl.0000251268.41188.04. Epub 2006 Dec 6.
Zotero 插件